Early safety study of berubicin in people whose brain tumors came back
Original title: Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a first test in people to find a safe dose, not proof that the drug works.
The short version
A first study in people tested a new drug for brain tumors that returned, mainly to find a safe dose.
What was studied. Thirty-five people with brain cancer that came back or stopped responding to treatment took part. Some had glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. They got a drug called berubicin through a vein for 3 days in a row, every 21 days.
What they found. The highest daily dose people could take safely was 7.5 mg/m2. Side effects outside the blood counts were small, and no heart damage was seen. Out of 35 people, 1 had a complete response that lasted, 1 had a partial response, and 9 had disease that stayed stable.
What this means, and what it doesn't
What it could mean: Berubicin was designed to cross into the brain. In this early study, doctors were able to give it with side effects that stayed low. A small number of people saw their tumor shrink or stop growing.
What it doesn't mean: This does not mean berubicin works. It was a first stage study in people. The main goal was to find a safe dose, not to show the drug helps people live longer. Most people in the study did not respond. The drug is not approved, and this is not a cure. It is still a long way from being care your doctor can offer.
Source: PubMed, July 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.